erlotinib hydrochloride has been researched along with oleic acid in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (oleic acid) | Trials (oleic acid) | Recent Studies (post-2010) (oleic acid) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 8,768 | 248 | 3,051 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | oleic acid (IC50) |
|---|---|---|---|
| Tyrosine-protein phosphatase non-receptor type 1 | Homo sapiens (human) | 6.2 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tan, S; Wang, G | 1 |
1 other study(ies) available for erlotinib hydrochloride and oleic acid
| Article | Year |
|---|---|
Redox-responsive and pH-sensitive nanoparticles enhanced stability and anticancer ability of erlotinib to treat lung cancer in vivo.
Topics: Acrylic Resins; Animals; Antineoplastic Agents; Cell Proliferation; Cystamine; Drug Delivery Systems; Drug Stability; Erlotinib Hydrochloride; Humans; Hydrogen-Ion Concentration; Lipids; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Molecular Structure; Nanoparticles; Neoplasms, Experimental; Oleic Acid; Oxidation-Reduction; Particle Size; Tumor Cells, Cultured | 2017 |